F2CS - Fast to Clinical Supply Platform

Your innovative therapy is ready to reach a key milestone with the IND date quickly approaching. You need a reliable partner to formulate and manufacture your therapy to meet the IND filing requirements and the dose needs for phase I studies fast. Every innovation is unique so your partner needs to offer the right mix of formulation and dosage form options and rapidly use data-driven models to determine the best option - not a one-size-fits-all mindset. WuXi STA's F2CS package applies our capability, expertise and advanced technology to deliver effective clinical trial material fast. F2CS is the abbreviation of Fast to Clinical Supply, representing the promise of formulation development and CTM supply both within 8 weeks. This is possible with flexible options custom developed by highly experiences integrated teams with advanced technologies, working in parallel to save time. Time is your greatest asset; partner with us today!